阿达木单抗治疗难治性活动性与非活动性非感染性葡萄膜炎
多中心回顾性病历审查研究,纳入22例患者37只眼,比较阿达木单抗在活动性与非活动性难治性非感染性葡萄膜炎中的疗效。结果显示活动眼治疗6个月时90%实现前房炎症2级改善,非活动眼94%维持临床静止,随访期间活动眼治疗失败发生率为88/100眼年,非活动眼为24/100眼年,无严重不良事件。
要点
- 活动眼治疗6个月时90%实现前房炎症2级改善,60%玻璃体混浊分级类似改善。
- 非活动眼94%在6个月时维持临床静止,治疗失败发生率为24/100眼年。
- 活动眼治疗失败发生率为88/100眼年,启动阿达木单抗时的炎症活动度可能决定长期治疗成功。
核心结论
- 在真实世界环境中,阿达木单抗似乎可减轻活动性与非活动性非感染性葡萄膜炎的皮质类固醇负担。
- 启动阿达木单抗时的炎症活动度可能决定长期治疗成功。
研究设计与样本
- 多中心、回顾性病历审查研究,纳入22例难治性非感染性葡萄膜炎患者的37只眼,接受阿达木单抗治疗。
- 主要结局指标包括泼尼松龙剂量减少、免疫抑制剂减量能力以及包含活动性炎症性脉络膜视网膜或视网膜血管病变、眼内炎症分级和视力的复合治疗失败终点。
- 平均随访20.1个月(中位数13个月),基线葡萄膜炎平均病程83.2个月(中位数61个月)。
主要发现
- 多数患者为后葡萄膜炎或全葡萄膜炎(n=12,55%),大多数(n=15,68%)在泼尼松龙之外已接受两种或以上传统免疫抑制剂治疗。
- 口服泼尼松龙在6周内减至≤10 mg/天的患者为12例中的9例(75%)。
- 治疗6个月时,活动眼中有9只(90%)实现前房炎症2级改善,6只(60%)玻璃体混浊分级出现类似改善。
- 治疗6个月时,初始非活动眼中几乎全部(n=17,94%)维持临床静止。
- 随访期间治疗失败发生率活动眼为88/100眼年,初始非活动眼为24/100眼年;未发生严重不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To compare the efficacy of adalimumab in eyes with active and inactive non-infectious uveitis in the real-world setting. METHODS: Multicentre, retrospective, chart review of patients with refractory non-infectious uveitis treated with adalimumab. Main outcome measures included reduction of prednisolone dose, ability to taper immunosuppressives and a composite endpoint of treatment failure encompassing active inflammatory chorioretinal or retinal vascular lesions, intraocular inflammation grade and visual acuity. RESULTS: Thirty-seven eyes of 22 patients were studied. Mean follow-up was 20.1 months (median: 13). Most had either posterior or panuveitis (n=12, 55%). Mean duration of uveitis at baseline was 83.2 months (median: 61), where the majority (n=15, 68%) had already been treated with two or more conventional immunosuppressive agents in addition to prednisolone. Oral prednisolone was reduced to ≤10 mg/day in 9 of 12 patients (75%) by 6 weeks. At 6 months of therapy, nine (90%) of the active eyes achieved a 2-step improvement in anterior chamber inflammation, with six (60%) demonstrating a similar improvement in vitreous haze grade. Almost all (n=17, 94%) of the initially inactive eyes maintained clinical quiescence at this time point. The incidence rate of treatment failure during follow-up was 88 per 100 eye-years for the active eyes and 24 per 100 eye-years for the initially inactive eyes. There were no serious adverse effects. CONCLUSION: Adalimumab appears to reduce the corticosteroid burden in active and inactive non-infectious uveitis in the real-world setting. Inflammatory activity at the time of adalimumab commencement may determine long-term treatment success.
引用
- Lee JT, Yates WB, Rogers S, et al. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol. 2018. PMID: 29459430. doi:10.1136/bjophthalmol-2017-311234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。